Street Watchdog Research Buyers of Celladon (CLDN)

Street Watchdog Research out positive on Celladon (NASDAQ: CLDN) following today's merger announcement.

"With no new financing necessary through 2016 and 4 development programs in the pipeline, 2 of which will obtain Phase 2 clinical results by late 2016, we view today’s opening price of $1.49 as a very attractive entry point," the firm said in a note.

You May Also Be Interested In

• Benchmark Reiterates Hold Rating on Netflix (NFLX) Ahead of Q2 Results
• Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'
• Helen of Troy (HELE) PT Raised to $28 at UBS Following Strong Q1 Results